DAILYZ HEALTH NEWS

Global obesity surge driving premature heart disease with peak rates now in people in their early 50s and fastest growth in South Asia, major ENDO 2026 study reports

A major study at ENDO 2026 finds global heart disease now peaks at ages 50-54, driven by rising obesity and fastest growth in South Asia.

$Semaglutide lowers fracture risk$

GLP-1 drugs like semaglutide linked to 15% lower fracture risk and greater weight loss in type 2 diabetes patients versus other obesity medications.

A study at ENDO 2026 found that type 2 diabetes patients who nap over 30 minutes have a higher risk of fatty liver disease.

Bangladesh’s measles outbreak has killed over 650 children, prompting WHO and UNICEF to launch emergency vaccinations for young children.

The FDA approved CASGEVY™, the first CRISPR gene-edited cell therapy, for severe sickle cell disease patients 12 and older with recurrent crises.

The WHO has not declared a global health emergency over the drug-resistant tuberculosis strain linked to U.S. travelers as of mid-2025.

The Biden administration announced a plan to cap insulin out-of-pocket costs at $35 monthly for all insured Americans, expanding beyond Medicare.

As of mid-2026, the FDA has not approved any gene-editing therapies for type 1 diabetes, with such treatments still in preclinical stages.

A six-month trial in NEJM found hybrid closed-loop insulin pumps improved A1c and reduced severe hypoglycemia in type 1 diabetes patients.

The FDA has not approved RebiQuent for moderate to severe atopic dermatitis; current oral treatments include abrocitinib and upadacitinib.